XML 18 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
Total
Preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (in shares) at Dec. 31, 2018   23 97,225,810        
Beginning balance at Dec. 31, 2018 $ 87,032,407 $ 0 $ 97,226 $ 707,794,215 $ (620,426,436) $ (528,867) $ 96,269
Issuance of common stock for cash (in shares)     183,200        
Issuance of common stock for cash 907,330   $ 183 907,147      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)     525,000        
Exercise of stock options for cash and vesting of RSUs, net of tax payments (719,397)   $ 525 (719,922)      
Equity component of issuance of convertible notes 15,752,698     15,752,698      
Stock-based compensation 3,432,796     3,432,796      
Acquisition of non-controlling interest in Geneos 3,030,107           3,030,107
Net loss attributable to common stockholders (29,288,867)       (29,219,262)   (69,605)
Unrealized gain (loss) on short-term investments, net of tax 819,177         819,177  
Ending balance (in shares) at Mar. 31, 2019   23 97,934,010        
Ending balance at Mar. 31, 2019 80,966,251 $ 0 $ 97,934 727,166,934 (649,645,698) 290,310 3,056,771
Beginning balance (in shares) at Dec. 31, 2018   23 97,225,810        
Beginning balance at Dec. 31, 2018 87,032,407 $ 0 $ 97,226 707,794,215 (620,426,436) (528,867) 96,269
Net loss attributable to common stockholders (58,867,943)            
Unrealized gain (loss) on short-term investments, net of tax 1,260,722            
Ending balance (in shares) at Jun. 30, 2019   23 98,584,371        
Ending balance at Jun. 30, 2019 56,478,073 $ 0 $ 98,584 731,819,389 (679,032,924) 731,855 2,861,169
Beginning balance (in shares) at Mar. 31, 2019   23 97,934,010        
Beginning balance at Mar. 31, 2019 80,966,251 $ 0 $ 97,934 727,166,934 (649,645,698) 290,310 3,056,771
Issuance of common stock for cash (in shares)     476,600        
Issuance of common stock for cash 1,388,986   $ 476 1,388,510      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)     173,761        
Exercise of stock options for cash and vesting of RSUs, net of tax payments (81,259)   $ 174 (81,433)      
Stock-based compensation 3,355,195     3,345,378     9,817
Cost of acquisition of non-controlling interest in Geneos (13,569)           (13,569)
Net loss attributable to common stockholders (29,579,076)       (29,387,226)   (191,850)
Unrealized gain (loss) on short-term investments, net of tax 441,545         441,545  
Ending balance (in shares) at Jun. 30, 2019   23 98,584,371        
Ending balance at Jun. 30, 2019 56,478,073 $ 0 $ 98,584 731,819,389 (679,032,924) 731,855 2,861,169
Beginning balance (in shares) at Dec. 31, 2019   23 101,361,034        
Beginning balance at Dec. 31, 2019 5,404,858 $ 0 $ 101,361 742,646,785 (739,785,655) 472,608 1,969,759
Issuance of common stock for cash (in shares)     43,148,952        
Issuance of common stock for cash 208,241,933   $ 43,149 208,198,784      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)     1,405,114        
Exercise of stock options for cash and vesting of RSUs, net of tax payments 3,100,703   $ 1,405 3,099,298      
Stock-based compensation 4,001,553     4,017,761     (16,208)
Acquisition of non-controlling interest in Geneos 2,169,998           2,169,998
Net loss attributable to common stockholders (33,135,404)       (32,541,054)   (594,350)
Unrealized gain (loss) on short-term investments, net of tax (1,929,538)         (1,929,538)  
Ending balance (in shares) at Mar. 31, 2020   23 145,915,100        
Ending balance at Mar. 31, 2020 187,854,103 $ 0 $ 145,915 957,962,628 (772,326,709) (1,456,930) 3,529,199
Beginning balance (in shares) at Dec. 31, 2019   23 101,361,034        
Beginning balance at Dec. 31, 2019 5,404,858 $ 0 $ 101,361 742,646,785 (739,785,655) 472,608 1,969,759
Net loss attributable to common stockholders (162,307,870)            
Unrealized gain (loss) on short-term investments, net of tax (1,082,638)            
Ending balance (in shares) at Jun. 30, 2020   9 158,756,411        
Ending balance at Jun. 30, 2020 186,360,469 $ 0 $ 158,756 1,087,745,242 (901,029,768) (610,030) 96,269
Beginning balance (in shares) at Mar. 31, 2020   23 145,915,100        
Beginning balance at Mar. 31, 2020 187,854,103 $ 0 $ 145,915 957,962,628 (772,326,709) (1,456,930) 3,529,199
Issuance of common stock for cash (in shares)     12,041,178        
Issuance of common stock for cash 121,718,922   $ 12,041 121,706,881      
Conversion of preferred stock to common stock (in shares)   (14) 5,147        
Conversion of preferred stock to common stock 0   $ 5 (5)      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)     794,986        
Exercise of stock options for cash and vesting of RSUs, net of tax payments 4,422,244   $ 795 4,421,449      
Stock-based compensation 3,662,435     3,654,289     8,146
Acquisition of non-controlling interest in Geneos 209,971           209,971
Deconsolidation of Geneos (3,181,640)           (3,181,640)
Net loss attributable to common stockholders (129,172,466)       (128,703,059)   (469,407)
Unrealized gain (loss) on short-term investments, net of tax 846,900         846,900  
Ending balance (in shares) at Jun. 30, 2020   9 158,756,411        
Ending balance at Jun. 30, 2020 $ 186,360,469 $ 0 $ 158,756 $ 1,087,745,242 $ (901,029,768) $ (610,030) $ 96,269